サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1756476

フィデューシャルマーカー市場：製品タイプ別、モダリティ別、がんタイプ別、エンドユーザー別、国別、地域別-2024年～2032年の産業分析、市場規模、市場シェア、予測

Fiducial Marker Market, By Product, By Modality, By Cancer Type, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 399 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
フィデューシャルマーカー市場：製品タイプ別、モダリティ別、がんタイプ別、エンドユーザー別、国別、地域別-2024年～2032年の産業分析、市場規模、市場シェア、予測
出版日: 2025年05月15日
発行: AnalystView Market Insights
ページ情報: 英文 399 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

フィデューシャルマーカー市場規模は2024年に1億6,890万米ドルとなり、2024～2032年にかけてCAGR 8.70%で拡大

フィデューシャルマーカー市場-市場力学

画像誘導治療の採用拡大

腫瘍学、神経学、循環器学における画像誘導治療の採用拡大が、フィデューシャルマーカー市場の主要な促進要因です。これらの治療法では、治療の精度を高め、合併症を減らすために、解剖学的標的の高精度な位置特定に大きく依存しています。フィデューシャルマーカーは、特に定位放射線手術や陽子線治療などの複雑な治療において、画像データを患者の解剖学的構造に合わせるための信頼できる基準点として重要な役割を果たしています。ヘルスケアプロバイダが低侵襲で標的を絞った治療をますます好むようになり、フィデューシャルの需要が急増しています。さらに、MRI、CT、ハイブリッドPET/CTシステムなどの画像技術の進歩により、多様な臨床現場でフィデューシャルマーカーの有用性が拡大しています。がんや慢性疾患の有病率の上昇は、正確な治療計画の必要性をさらに高め、フィデューシャルマーカーを現代の治療ワークフローに不可欠なツールとして位置付けています。この動向は、市場の持続的成長を促進すると予想されます。

フィデューシャルマーカー市場-主要な洞察

当社のリサーチアナリストによると、世界のフィデューシャルマーカー市場は、2024～2032年にかけて約8.70%のCAGRで発展する見込みです。

2024年の製品別セグメントでは、金属ベースのマーカーカテゴリが市場を独占しています。

モダリティ別では、超音波が2024年に最も収益を上げました。

地域別では、2024年に北米が最も収益が高かったです。

フィデューシャルマーカー市場-セグメンテーション分析

世界のフィデューシャルマーカー市場は4つのカテゴリーに分類されます：製品、モダリティ、がんタイプ、エンドユーザー、地域です。

フィデューシャルマーカー市場は、製品別に金属ベースのマーカー、ポリマーベースマーカー、その他のフィデューシャルマーカーに区分されます。なかでも金属ベースマーカーは、視認性に優れ、CT、MRI、X線などさまざまな画像診断モダリティに適合することから、市場を席巻することが予想されます。通常、金、プラチナ、ステンレスから作られるこれらのマーカーは、高いコントラストと体内での長期安定性を提供するため、放射線治療計画や画像誘導手術など、繰り返し撮像を必要とする処置に最適です。耐久性に優れ、移動のリスクが低いため、特に腫瘍学的な用途において、手技の正確性が向上します。金属ベースのフィデューシャルが臨床的に広く受け入れられていることに加え、治療成績の改善におけるその有効性が実証されていることが、市場でのリーダーシップをさらに支えています。精密医療と低侵襲治療の需要が拡大し続ける中、金属ベースのマーカーの堅牢な性能と信頼性は、世界のヘルスケアシステム全体で好ましい選択肢として位置づけられています。

フィデューシャルマーカー市場をがんタイプ別に分類すると、前立腺がん、肺がん、胃がん、乳がん、その他のがんなどがあります。このうち、前立腺がんが最大のシェアを占めており、今後も支配的なセグメントであり続けると予想されています。これは、前立腺がん治療のための画像誘導放射線治療（IGRT）や定位体放射線治療（SBRT）において、フィデューシャルマーカーが広く使用されていることが主要原因です。前立腺は膀胱や直腸の充満によりわずかに移動する傾向があり、正確な位置特定が重要になります。金属ベースのフィデューシャルマーカー、特に金マーカーは、各治療セッション中の正確なターゲティングを確実にし、周囲組織への損傷を最小限に抑えながら治療成績を改善するために、前立腺にルーチンに埋め込まれています。前立腺がんの世界の罹患率の上昇と、先進的な放射線治療技術に対する認識と採用の増加が、このセグメントにおけるフィデューシャルマーカーの持続的な需要を牽引しています。臨床プロトコルの充実と償還サポートが、この市場の優位性をさらに高めています。

フィデューシャルマーカー市場-地理的洞察

フィデューシャルマーカー市場は、北米、アジア太平洋、ラテンアメリカ、欧州、中東・アフリカに分布しています。これらの地域は、ビジネスをもたらしている国に基づいてさらに分割されます。

北米はフィデューシャルマーカー市場で支配的な地位を占めており、その主要因は先進ヘルスケアインフラ、画像誘導治療の高い導入率、がん治療技術への多額の投資です。特に米国は、がん、特に前立腺がんや肺がんの有病率が高く、フィデューシャルマーカーのような正確な診断・治療ツールの需要を牽引しているため、市場をリードしています。さらに、確立されたヘルスケアシステムと相まって、強力な償還施策が放射線治療や外科手術におけるフィデューシャルの普及を促進しています。さらに、低侵襲治療と画像技術に関する継続的な研究と技術革新が、市場の成長を支え続けています。この地域の優位性は、主要市場参入企業の存在も支えており、採用や製品開拓をさらに促進しています。

欧州もフィデューシャルマーカー市場に大きく貢献している主要地域です。先進的ヘルスケア技術の採用と、精密医療や標的を絞ったがん治療の重視の高まりが、この地域におけるフィデューシャルマーカーの需要を促進しています。ドイツ、英国、フランス、イタリアなどの国々は、高度に発達したヘルスケアシステムとがん罹患率の増加により市場をリードしています。欧州のヘルスケアプロバイダは、特に前立腺がん、乳がん、肺がんなどの画像誘導放射線治療にフィデューシャルマーカーを利用するようになっています。この地域の強力な規制の枠組みは、臨床研究や技術革新への支援とともに、フィデューシャルマーカー使用の成長に道を開いています。さらに、低侵襲治療への嗜好の高まりや、患者の予後改善への注目の高まりが、市場をさらに押し上げています。

フィデューシャルマーカー市場-競合情勢

フィデューシャルマーカー市場の競合力学は、既存参入企業と技術革新に注力する新興企業の混合によって形成されています。CIVCO RadIoTherapy、Boston Scientific Corporation、IZI Medical Products、Medtronic、IBAなどの主要企業が大きなシェアを占めており、さまざまな医療画像用途に合わせた高品質のフィデューシャルマーカーを幅広く提供しています。これらの企業は研究開発に多額の投資を行い、製品の機能強化、精度向上、規制遵守を図っています。Nanovi A/SやInnovative Oncology Solutionsのような新規参入企業は、視認性と埋め込みやすさを強化した次世代フィデューシャルのような先進技術を導入しています。このような競合情勢は、このセグメントにおける絶え間ない進歩を促し、最終的に手技の精度と有効性を向上させるイノベーションの環境を醸成しています。例えば、メドトロニックは、継続的な研究開発と先進画像技術の開発により、このセグメントでの技術革新を続け、市場でのリーダーシップを維持しています。

目次

第1章 フィデューシャルマーカー市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 フィデューシャルマーカーの主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 フィデューシャルマーカー産業調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長展望マッピング
  • 規制枠組み分析

第5章 フィデューシャルマーカー市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 フィデューシャルマーカー市場情勢

  • フィデューシャルマーカー市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • ベテラン選手の分析
    • 新興企業の分析

第7章 フィデューシャルマーカー市場-製品別

  • 概要
    • 製品別セグメントシェア分析
    • 金属ベースのマーカー
      • 純金マーカー
      • ゴールドコンビネーションマーカー
      • その他の金属ベースのマーカー
    • ポリマーベースのマーカー
    • その他の基準マーカー

第8章 フィデューシャルマーカー市場-モダリティ別

  • 概要
    • モダリティ別セグメントシェア分析
    • CT/CBCT
    • 超音波
    • MRI
    • 放射線療法

第9章 フィデューシャルマーカー市場-がんタイプ別

  • 概要
    • がんタイプ別セグメントシェア分析
    • 前立腺がん
    • 肺がん
    • 胃がん
    • 乳がん
    • その他のがん

第10章 フィデューシャルマーカー市場-エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院と外来施設
    • 独立放射線治療センター
    • がん研究センター

第11章 フィデューシャルマーカー市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析-フィデューシャルマーカー産業

  • 競合ダッシュボード
    • 競合ベンチマーキング
    • 競合ポジショニング
  • 企業プロファイル
    • CIVCO RadIoTherapy
    • Boston Scientific Corporation
    • IZI Medical Products
    • IBA
    • Naslund Medical AB
    • Medtronic
    • Best Medical International, Inc.
    • Nanovi A/S
    • Carbon Medical Technologies
    • Eckert & Ziegler
    • Innovative Oncology Solutions
    • QlRad Inc.
    • Stellar Medical
    • JJ-Medtech
    • QFIX
    • その他

第13章 アナリストの全方位展望

目次
Product Code: ANV5293

REPORT HIGHLIGHT

Fiducial Marker Market size was valued at USD 168.9 Million in 2024, expanding at a CAGR of 8.70% from 2024 to 2032.

In healthcare, a fiducial marker is a reference point or object placed in or on the body to assist with precise localization during medical imaging, diagnostic procedures, or treatment planning. These markers are commonly used in radiology, radiation therapy, and surgical navigation to align imaging data with anatomical structures. Fiducial markers can be external (placed on the skin) or internal (implanted into tissues or tumors). Materials such as gold, carbon, or polymer are often used due to their visibility in imaging modalities like CT, MRI, and X-rays. In cancer treatment, for example, fiducial markers are implanted near tumors to help guide radiation beams with high accuracy, minimizing damage to healthy tissue. Similarly, in neurosurgery or robotic-assisted surgeries, fiducials provide reference points that enhance navigation systems. Their use significantly improves procedural precision, outcomes, and patient safety by ensuring accurate targeting and consistent positioning throughout treatment or surgical interventions.

Fiducial Marker Market- Market Dynamics

Increasing Adoption of Image-Guided Therapies

The growing adoption of image-guided therapies in oncology, neurology, and cardiology is a key driver for the fiducial markers market. These procedures rely heavily on high-precision localization of anatomical targets to enhance treatment accuracy and reduce complications. Fiducial markers play a crucial role by serving as reliable reference points for aligning imaging data with the patient's anatomy, especially in complex interventions such as stereotactic radiosurgery or proton therapy. As healthcare providers increasingly prefer minimally invasive and targeted treatment options, the demand for fiducials has surged. Moreover, advancements in imaging technologies, including MRI, CT, and hybrid PET/CT systems, have expanded the utility of fiducial markers across diverse clinical settings. The rising prevalence of cancer and chronic diseases further contributes to the need for accurate treatment planning, positioning fiducial markers as an essential tool in modern therapeutic workflows. This trend is expected to drive sustained market growth.

FIDUCIAL MARKER Market- Key Insights

According to our research analyst, the global Fiducial Marker Market is expected to develop at a CAGR of approximately 8.70% between 2024-2032.

Segmented by Product in 2024, the Metal-Based Markers category dominated the market.

Based on Modality, the Ultrasound generated the most income in 2024.

Based on region, in 2024, North America was the region with the highest revenue.

Fiducial Marker Market- Segmentation Analysis:

The global Fiducial Marker market is divided into four categories: Product, Modality, Cancer Type, End User and Region.

The fiducial markers market is segmented by product into Metal-Based Markers, Polymer-Based Markers, and Other Fiducial Markers. Among these, Metal-Based Markers are expected to dominate the market due to their superior visibility and compatibility with various imaging modalities such as CT, MRI, and X-ray. Typically made from gold, platinum, or stainless steel, these markers provide high contrast and long-term stability within the body, making them ideal for procedures requiring repeated imaging, such as radiotherapy planning and image-guided surgery. Their durability and low risk of migration enhance procedural accuracy, particularly in oncology applications. The widespread clinical acceptance of metal-based fiducials, along with their proven efficacy in improving treatment outcomes, further supports their market leadership. As the demand for precision medicine and minimally invasive treatments continues to grow, the robust performance and reliability of metal-based markers position them as the preferred choice across global healthcare systems.

The fiducial markers market, when segmented by cancer type, includes Prostate Cancer, Lung Cancer, Gastric Cancer, Breast Cancer, and Other Cancers. Among these, Prostate Cancer accounts for the largest share and is expected to remain the dominant segment. This is largely due to the widespread use of fiducial markers in image-guided radiation therapy (IGRT) and stereotactic body radiation therapy (SBRT) for prostate cancer treatment. The prostate gland tends to shift slightly due to bladder and rectal filling, making accurate localization critical. Metal-based fiducial markers, especially gold markers, are routinely implanted in the prostate to ensure precise targeting during each treatment session, improving outcomes while minimizing damage to surrounding tissues. The rising global incidence of prostate cancer, along with increased awareness and adoption of advanced radiotherapy techniques, is driving the sustained demand for fiducial markers in this segment. Enhanced clinical protocols and reimbursement support further contribute to its market dominance.

Fiducial Marker Market- Geographical Insights

Geographically, the Fiducial Marker Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.

North America holds a dominant position in the fiducial marker market, primarily driven by advanced healthcare infrastructure, high adoption rates of image-guided therapies, and significant investments in cancer treatment technologies. The United States, in particular, leads the market due to the high prevalence of cancer, especially prostate and lung cancer, which drives the demand for accurate diagnostic and therapeutic tools such as fiducial markers. Additionally, strong reimbursement policies, coupled with a well-established healthcare system, facilitate the widespread usage of fiducials in radiotherapy and surgical procedures. Furthermore, ongoing research and innovation in minimally invasive treatments and imaging technologies continue to support market growth. The region's dominance is also supported by the presence of key market players, further driving adoption and product development.

Europe is another key region contributing significantly to the fiducial marker market. The adoption of advanced healthcare technologies, coupled with a growing emphasis on precision medicine and targeted cancer therapies, has fostered the demand for fiducial markers in the region. Countries such as Germany, the UK, France, and Italy lead the market, owing to their highly developed healthcare systems and increasing cancer incidence rates. European healthcare providers are increasingly utilizing fiducial markers in image-guided radiation therapy, particularly for prostate, breast, and lung cancers. The region's strong regulatory frameworks, along with the support for clinical research and innovation, have paved the way for the growth of fiducial marker usage. Furthermore, the increasing preference for minimally invasive treatments and the growing focus on improving patient outcomes further boost the market.

Fiducial Marker Market- Competitive Landscape:

The competitive dynamics of the Fiducial Marker market are shaped by a mix of established players and emerging companies focused on innovation. Key market players such as CIVCO Radiotherapy, Boston Scientific Corporation, IZI Medical Products, Medtronic, and IBA hold significant market shares, offering a wide range of high-quality fiducial markers tailored for various medical imaging applications. These companies invest heavily in research and development to enhance product features, improve precision, and ensure regulatory compliance. New entrants, like Nanovi A/S and Innovative Oncology Solutions, are introducing advanced technologies such as next-gen fiducials with enhanced visibility and ease of implantation. This competitive landscape drives continuous advancements in the sector, fostering an environment of innovation that ultimately improves the accuracy and effectiveness of procedures. For instance, Medtronic continues to innovate in the field with its ongoing R&D and the development of advanced imaging technologies, maintaining its leadership in the market.

Recent Developments:

In October 2023, Nanovi A/S, a Danish medical device company specializing in liquid fiducial markers, was acquired by CQ Medical (formerly CIVCO Radiotherapy and Qfix). This acquisition integrates Nanovi's innovative BioXmark(R) technology into CQ Medical's portfolio, enhancing its offerings in high-precision radiation therapy. BioXmark(R) is a biodegradable liquid marker that provides excellent imaging visibility with minimal artifacts, making it suitable for various imaging modalities, including CT and MRI.

In June 2023, CIVCO Radiotherapy expanded its portfolio with the acquisition of Best Medical International, Inc., further strengthening its position in the fiducial marker market.

In February 2022, Boston Scientific Corporation launched a new fiducial marker designed for enhanced MRI compatibility, offering improved patient safety and treatment accuracy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FIDUCIAL MARKER MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • CIVCO Radiotherapy
  • Boston Scientific Corporation
  • IZI Medical Products
  • IBA
  • Naslund Medical AB
  • Medtronic
  • Best Medical International, Inc.
  • Nanovi A/S
  • Carbon Medical Technologies
  • Eckert & Ziegler
  • Innovative Oncology Solutions
  • QlRad Inc.
  • Stellar Medical
  • JJ-Medtech
  • QFIX
  • Others

GLOBAL FIDUCIAL MARKER MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

  • Metal-Based Markers
  • Pure Gold Markers
  • Gold Combination Markers
  • Other Metal-Based Markers
  • Polymer-Based Markers
  • Other Fiducial Markers

GLOBAL FIDUCIAL MARKER MARKET, BY MODALITY - MARKET ANALYSIS, 2019 - 2032

  • CT/CBCT
  • Ultrasound
  • MRI
  • Radiotherapy

GLOBAL FIDUCIAL MARKER MARKET, BY CANCER TYPE - MARKET ANALYSIS, 2019 - 2032

  • Prostate Cancer
  • Lung Cancer
  • Gastric Cancer
  • Breast Cancer
  • Other Cancers

GLOBAL FIDUCIAL MARKER MARKET, BY END USER - MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Outpatient Facilities
  • Independent Radiotherapy Centers
  • Cancer Research Centers

GLOBAL FIDUCIAL MARKER MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Fiducial Marker Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Fiducial Marker Market Snippet by Product
    • 2.1.2. Fiducial Marker Market Snippet by Modality
    • 2.1.3. Fiducial Marker Market Snippet by Cancer Type
    • 2.1.4. Fiducial Marker Market Snippet by End User
    • 2.1.5. Fiducial Marker Market Snippet by Country
    • 2.1.6. Fiducial Marker Market Snippet by Region
  • 2.2. Competitive Insights

3. Fiducial Marker Key Market Trends

  • 3.1. Fiducial Marker Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Fiducial Marker Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Fiducial Marker Market Opportunities
  • 3.4. Fiducial Marker Market Future Trends

4. Fiducial Marker Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Fiducial Marker Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Fiducial Marker Market Landscape

  • 6.1. Fiducial Marker Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Fiducial Marker Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2023 & 2032 (%)
    • 7.1.2. Metal-Based Markers
      • 7.1.2.1. Pure Gold Markers
      • 7.1.2.2. Gold Combination Markers
      • 7.1.2.3. Other Metal-Based Markers
    • 7.1.3. Polymer-Based Markers
    • 7.1.4. Other Fiducial Markers

8. Fiducial Marker Market - By Modality

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Modality, 2023 & 2032 (%)
    • 8.1.2. Ct/Cbct
    • 8.1.3. Ultrasound
    • 8.1.4. MRI
    • 8.1.5. Radiotherapy

9. Fiducial Marker Market - By Cancer Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Cancer Type, 2023 & 2032 (%)
    • 9.1.2. Prostate Cancer
    • 9.1.3. Lung Cancer
    • 9.1.4. Gastric Cancer
    • 9.1.5. Breast Cancer
    • 9.1.6. Other Cancers

10. Fiducial Marker Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospitals & Outpatient Facilities
    • 10.1.3. Independent Radiotherapy Centers
    • 10.1.4. Cancer Research Centers

11. Fiducial Marker Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Fiducial Marker Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Fiducial Marker Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Fiducial Marker Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Fiducial Marker Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Fiducial Marker Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Modality, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Fiducial Marker Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. CIVCO Radiotherapy
    • 12.2.2. Boston Scientific Corporation
    • 12.2.3. IZI Medical Products
    • 12.2.4. IBA
    • 12.2.5. Naslund Medical AB
    • 12.2.6. Medtronic
    • 12.2.7. Best Medical International, Inc.
    • 12.2.8. Nanovi A/S
    • 12.2.9. Carbon Medical Technologies
    • 12.2.10. Eckert & Ziegler
    • 12.2.11. Innovative Oncology Solutions
    • 12.2.12. QlRad Inc.
    • 12.2.13. Stellar Medical
    • 12.2.14. JJ-Medtech
    • 12.2.15. QFIX
    • 12.2.16. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us